更紧凑的生命科学资讯库。
先搜索,再按来源或主题继续收窄。
Moderna继续重组,再砍三条研发管线
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines...
眼疾治疗管线下一步进展如何?
What’s next in the eye disease pipeline? An early gene therapy breakthrough spurred investments, but can the industry maintain momentum? Published Nov. 24, 2025 By Kell...
罗氏早期giredestrant成果获赞 | ApexOnco - 临床试验新闻与分析 - 肿瘤学研发管线
Roche touts early giredestrant success | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
罗氏制药管线进展与股价飙升17%后,是否该重新评估其投资时机? - simplywall.st
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? simplywall.st
罗氏盈利展望:微调2025年销售预期,但多元化研发管线令人鼓舞——晨星加拿大
Roche Earnings: We’re Slightly Lowering Our 2025 Sales Forecast but Encouraged by Diverse Pipeline Morningstar Canada
罗氏推进新型骨髓瘤靶点研究 | ApexOnco - 临床试验新闻与分析 - 肿瘤学研发管线
Roche pushes a novel myeloma target | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
罗氏凭借divarasib提前布局 | ApexOnco - 临床试验新闻与分析 - 肿瘤学研发管线
Roche looks earlier with divarasib | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
罗氏在5,000名患者试验后放弃其TIGIT项目 | ApexOnco - 临床试验新闻与分析 - 肿瘤学研发管线
5,000 patients later Roche scraps its TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
把品牌目录放在视野里,但不抢主叙事
把工具、CRO、生物制药和器械公司做成滚动资源带,作为资讯流下方的辅助索引。
查看关于页